Aan onderstaand bericht hebben we het korte abstract toegevoegd van een dubbelblinde gerandomiseerde studie bij blaaskankerpatienten die aanvullend ook oraal probiotica - melkzuurbacterien namen. Ook deze studie bewijst dat aanvullend melkzuurbacterien significant de recidiefvrije tijd van blaaskankerpatienten met niet invasieve tumoren kan verlengen. Zie ook studie uit 2008 onder dit abstract:

Eur Urol. 1995;27(2):104-9.

Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group.

Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S.

Department of Urology, Faculty of Medicine, University of Tokyo, Japan.

A double-blind trial was conducted in 138 patients with superficial transitional cell carcinoma of the bladder following transurethral resection to evaluate the prophylaxis of recurrence by an oral Lactobacillus casei preparation (BLP). Patients were stratified into the following 3 subgroups: (A) with primary multiple tumors; (B) with recurrent single tumors, and (C) with recurrent multiple tumors. In each group, patients were randomly allocated to receive BLP or placebo. BLP showed a better prophylactic effect in subgroups A and B than placebo, whereas no significant difference was observed in subgroup C. Cox multivariate analysis showed that the outcome with BLP was significantly better than with placebo (p = 0.01). Slight and tolerable adverse reactions occurred in 3 patients receiving BLP and in 3 of the placebo-treated patients. Oral administration of BLP was thus safe and effective for preventing recurrence of superficial bladder cancer.

PMID: 7744150 [PubMed - indexed for MEDLINE]

31 augustus 2008: Bron: 1: J Urol. 2008 Feb;179(2):485-90. Links

Een jaar lang melkzuurbacterien oraal ingenomen en toegevoegd aan behandeling met epirubicine na operatieve verwijdering van blaaskankertumoren geeft blaaskankerpatienten een beduidend grotere kans op wegblijven van een recidief dan alleen epirubicine. De 3-jaars ziektevrije overlevingstijd was significant hoger in de epirubicin plus Lactobacillus casei groep dan in de epirubicin groep (74.6% vs 59.9%, p = 0.0234).

Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer.

Naito S, Koga H, Yamaguchi A, Fujimoto N, Hasui Y, Kuramoto H, Iguchi A, Kinukawa N; Kyushu University Urological Oncology Group.

Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

PURPOSE: A prospective, randomized, controlled trial was done to evaluate whether oral administration of a preparation of the probiotic agent Lactobacillus casei (Yakult Honsha, Tokyo, Japan) could enhance the prevention of recurrence by intravesical instillation of epirubicin after transurethral resection for superficial bladder cancer.

MATERIALS AND METHODS: Between August 1999 and December 2002, 207 patients clinically diagnosed with superficial bladder cancer were included as study candidates and underwent transurethral resection, followed by intravesical instillation of 30 mg epirubicin/30 ml saline twice during 1 week. After histological confirmation of superficial bladder cancer they were again included as study participants with 102 randomized to receive treatment with 6 additional intravesical instillations of epirubicin during the 3-month period after transurethral resection (epirubicin group) and 100 randomized to intravesical chemotherapy on the same schedule as the epirubicin group plus oral administration of 3 gm Lactobacillus casei preparation per day for 1 year (epirubicin plus Lactobacillus casei group). Patients were evaluated for intravesical recurrence, disease progression, prognosis and adverse drug reactions.

RESULTS: The 3-year recurrence-free survival rate was significantly higher in the epirubicin plus Lactobacillus casei group than in the epirubicin group (74.6% vs 59.9%, p = 0.0234), although neither progression-free nor overall survival differed between the groups. The incidence of adverse drug reactions did not significantly differ between the groups and there were no serious adverse drug reactions.

CONCLUSIONS: Intravesical instillation of epirubicin plus oral administration of Lactobacillus casei preparation is a novel, promising treatment for preventing recurrence after transurethral resection for superficial bladder cancer.

PMID: 18076918 [PubMed - indexed for MEDLINE]

epirubicine, probiotica, blaaskanker